CN112438971A - Application of methionine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection - Google Patents
Application of methionine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection Download PDFInfo
- Publication number
- CN112438971A CN112438971A CN202011556378.1A CN202011556378A CN112438971A CN 112438971 A CN112438971 A CN 112438971A CN 202011556378 A CN202011556378 A CN 202011556378A CN 112438971 A CN112438971 A CN 112438971A
- Authority
- CN
- China
- Prior art keywords
- injection
- puerarin
- methionine
- hemolysis
- solution
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- RXUWDKBZZLIASQ-UHFFFAOYSA-N Puerarin Natural products OCC1OC(Oc2c(O)cc(O)c3C(=O)C(=COc23)c4ccc(O)cc4)C(O)C(O)C1O RXUWDKBZZLIASQ-UHFFFAOYSA-N 0.000 title claims abstract description 123
- HKEAFJYKMMKDOR-VPRICQMDSA-N puerarin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1C1=C(O)C=CC(C2=O)=C1OC=C2C1=CC=C(O)C=C1 HKEAFJYKMMKDOR-VPRICQMDSA-N 0.000 title claims abstract description 123
- 239000007924 injection Substances 0.000 title claims abstract description 122
- 238000002347 injection Methods 0.000 title claims abstract description 122
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 title claims abstract description 67
- 229930182817 methionine Natural products 0.000 title claims abstract description 67
- 206010018910 Haemolysis Diseases 0.000 title claims description 39
- 239000003814 drug Substances 0.000 title claims description 21
- 206010022822 Intravascular haemolysis Diseases 0.000 title claims description 7
- 239000000243 solution Substances 0.000 claims description 28
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 27
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims description 14
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 9
- 239000008103 glucose Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 238000001802 infusion Methods 0.000 claims description 7
- 235000017557 sodium bicarbonate Nutrition 0.000 claims description 7
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims description 7
- 239000008354 sodium chloride injection Substances 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims 1
- 206010067484 Adverse reaction Diseases 0.000 abstract description 18
- 230000006838 adverse reaction Effects 0.000 abstract description 18
- 238000000034 method Methods 0.000 abstract description 7
- 230000002949 hemolytic effect Effects 0.000 abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 31
- 230000008588 hemolysis Effects 0.000 description 31
- 241000283973 Oryctolagus cuniculus Species 0.000 description 15
- 150000001875 compounds Chemical class 0.000 description 15
- 238000012360 testing method Methods 0.000 description 13
- 210000003743 erythrocyte Anatomy 0.000 description 12
- 239000011780 sodium chloride Substances 0.000 description 12
- 230000001954 sterilising effect Effects 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 11
- 239000000843 powder Substances 0.000 description 11
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 10
- 229940079593 drug Drugs 0.000 description 9
- 238000001914 filtration Methods 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 239000000706 filtrate Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- 206010002383 Angina Pectoris Diseases 0.000 description 5
- 239000003708 ampul Substances 0.000 description 5
- 208000026106 cerebrovascular disease Diseases 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 206010012601 diabetes mellitus Diseases 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 239000008215 water for injection Substances 0.000 description 5
- MEFKEPWMEQBLKI-AIRLBKTGSA-N S-adenosyl-L-methioninate Chemical compound O[C@@H]1[C@H](O)[C@@H](C[S+](CC[C@H](N)C([O-])=O)C)O[C@H]1N1C2=NC=NC(N)=C2N=C1 MEFKEPWMEQBLKI-AIRLBKTGSA-N 0.000 description 4
- 206010061373 Sudden Hearing Loss Diseases 0.000 description 4
- 229960001570 ademetionine Drugs 0.000 description 4
- 208000029078 coronary artery disease Diseases 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 4
- 208000007475 hemolytic anemia Diseases 0.000 description 4
- 230000000302 ischemic effect Effects 0.000 description 4
- 208000010125 myocardial infarction Diseases 0.000 description 4
- 230000035484 reaction time Effects 0.000 description 4
- 210000001927 retinal artery Anatomy 0.000 description 4
- 210000001957 retinal vein Anatomy 0.000 description 4
- 239000006228 supernatant Substances 0.000 description 4
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 4
- 206010047470 viral myocarditis Diseases 0.000 description 4
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 238000009098 adjuvant therapy Methods 0.000 description 3
- 230000004520 agglutination Effects 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 238000010253 intravenous injection Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 238000004806 packaging method and process Methods 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 235000018102 proteins Nutrition 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 206010061623 Adverse drug reaction Diseases 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 206010037660 Pyrexia Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000003042 antagnostic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 239000006285 cell suspension Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- CJWQYWQDLBZGPD-UHFFFAOYSA-N isoflavone Natural products C1=C(OC)C(OC)=CC(OC)=C1C1=COC2=C(C=CC(C)(C)O3)C3=C(OC)C=C2C1=O CJWQYWQDLBZGPD-UHFFFAOYSA-N 0.000 description 2
- 235000008696 isoflavones Nutrition 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 230000011987 methylation Effects 0.000 description 2
- 238000007069 methylation reaction Methods 0.000 description 2
- 239000012982 microporous membrane Substances 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 238000004659 sterilization and disinfection Methods 0.000 description 2
- 229960003080 taurine Drugs 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- 206010002199 Anaphylactic shock Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000003952 Caspase 3 Human genes 0.000 description 1
- 108090000397 Caspase 3 Proteins 0.000 description 1
- 206010051055 Deep vein thrombosis Diseases 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 208000032131 Diabetic Neuropathies Diseases 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000220485 Fabaceae Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 235000010575 Pueraria lobata Nutrition 0.000 description 1
- 241000219781 Pueraria montana var. lobata Species 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000007718 Stable Angina Diseases 0.000 description 1
- 206010044565 Tremor Diseases 0.000 description 1
- 206010047249 Venous thrombosis Diseases 0.000 description 1
- 208000012886 Vertigo Diseases 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 230000004900 autophagic degradation Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000005779 cell damage Effects 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000002490 cerebral effect Effects 0.000 description 1
- 206010008118 cerebral infarction Diseases 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000006482 condensation reaction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 229960002433 cysteine Drugs 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- 230000000916 dilatatory effect Effects 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- ZFGMDIBRIDKWMY-PASTXAENSA-N heparin Chemical compound CC(O)=N[C@@H]1[C@@H](O)[C@H](O)[C@@H](COS(O)(=O)=O)O[C@@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O[C@H]2[C@@H]([C@@H](OS(O)(=O)=O)[C@@H](O[C@@H]3[C@@H](OC(O)[C@H](OS(O)(=O)=O)[C@H]3O)C(O)=O)O[C@@H]2O)CS(O)(=O)=O)[C@H](O)[C@H]1O ZFGMDIBRIDKWMY-PASTXAENSA-N 0.000 description 1
- 229960001008 heparin sodium Drugs 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000015788 innate immune response Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- -1 isoflavone compound Chemical class 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- 230000036284 oxygen consumption Effects 0.000 description 1
- 230000003617 peroxidasic effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 239000003642 reactive oxygen metabolite Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002604 ultrasonography Methods 0.000 description 1
- 231100000889 vertigo Toxicity 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The invention relates to a compatible application method of methionine and puerarin, which is characterized in that the methionine and the puerarin are prepared into an injection containing the puerarin, or the methionine is firstly used and then the puerarin is used, thereby effectively overcoming the accidental hemolytic adverse reaction of the puerarin injection and improving the safety of the puerarin injection administration.
Description
Technical Field
The invention relates to a medical application of methionine, in particular to an application in puerarin injection.
Background
The methionine is taken as a substrate for protein biosynthesis and can directly participate in the synthesis of proteins of organisms, and the methionine can be activated to generate S-adenosyl methionine (SAM) which is taken as a donor of methyl and sulfydryl, participates in the methylation of DNA, RNA, protein and the like in vivo and also participates in the synthesis of a plurality of bioactive substances such as polyamine, cysteine, glutathione, taurine and the like, thereby regulating and controlling the main physiological functions of animals. Reactive oxygen species (reactive)
oxidative species, ROS) can cause an imbalance in oxidative and antioxidant effects, leading to lipid peroxidative damage to proteins and DNA, which in turn leads to cell damage or apoptosis. Methionine exerts an antioxidant function in vivo mainly through a glutathione pathway and a redox pathway, and through the regulation of the production of antioxidant metabolites such as taurine and H2S in a transsulfuration pathway. Methionine regulates the immune state of the body by promoting the growth and development of immune organs, the proliferation of immune cells, and the involvement in the synthesis of immune molecules (cytokines, antibodies, complement, etc.). The lack of methionine promotes the apoptosis of the porcine epithelial cells infected with the ETEC, and simultaneously shows the characteristics of enhanced adhesion with the ETEC, reduced autophagy and the like. The methyl donor SAM in the methionine cycle promotes the development and functional expression of cells by participating in the methylation modification of proteins and nucleic acids. SAM can regulate the production and expression of some key cytokines such as TNF, IL-10 and IL-6, and can promote the proliferation activation of Th cells by relieving the reduction of caspase-3 activity induced by oxidative stress and reducing apoptosis, thereby participating in specific and non-specific immune responses.
Puerarin is an isoflavone compound extracted from dried root of Pueraria lobata Ohwi of Leguminosae, 4', 7-dihydroxy-8-beta-D-glucosyl isoflavone. Is widely used for treating cardiovascular diseases clinically. The prior clinical medicine preparation containing puerarin is mainly injection. With the wide use of puerarin, more and more reports about adverse reactions of puerarin are provided in recent years, and the wide attention of the medical field is attracted. By analyzing the adverse reaction of the traditional Chinese medicine in the last 20 years, the puerarin injection is ranked at the 18 th position. The national adverse drug reaction monitoring center reported adverse reactions of puerarin injection in adverse drug reaction information report 3 of 1 month in 2003. Most researchers think that the puerarin injection is prepared by using 50% propylene glycol as a solvent, so that the purity is not enough due to the difference of extraction processes, technologies and the like, and various reactions caused by introducing impurities cannot be avoided (see the analysis of adverse reactions in clinical puerarin injection in xu daohui, Shanghai J.Med., 2006, 40 (8): 71-72; and the clinical application and adverse reactions of puerarin in Xu Shi Guo, Shizhen Chinese medicine, 2005, 16 (12): 1307-1308). After 63 adverse reactions of puerarin reported in main medical journal in 2004 in 2000-year, 40 men and 23 women were discovered; the age is 34-81 (57.5 +/-23.5). In all cases intravenous drip was administered. The administration dosage is 0.4-0.6 g, and the drug diluent is 5% glucose solution, normal saline, 5% glucose saline and the like. The fastest reaction time is 3 min, the slowest reaction time is 13 d, and the reaction time is in the administration process. 47 responders appeared with the first dose and 16 responders appeared with repeated doses. Statistics show that the common adverse reactions include allergy (fever, tremor and the like, 24 cases), anaphylactic shock (4 cases), hemolytic anemia (13 cases), liver damage, kidney damage (7 cases), drug fever (10 cases) and death (5 cases). All cases had no history of allergy, and the patients who stopped taking the drug after the reaction were recovered by symptomatic treatment (except dead cases). The dosage and the used diluent are within the prompting range of the medicine instruction, and all reactions are definitely caused by puerarin. The adverse reaction is independent of the disease, age and sex, and is not related to the drug diluent. It is related to the difference in constitutions of patients, especially the elderly and infirm. The length of the reaction time is related to the slow onset of action of the Chinese medicinal preparation (see the general Rongrong written analysis of 63 cases of adverse reactions of puerarin documents, journal of the modern Chinese and Western medicine combination, 2005, 14 (1): 140). A patient with intravenous injection of puerarin shows acute renal insufficiency and hemolytic anemia after about 10min (see Kunming written "puerarin induced hemolytic anemia", journal of adverse drug reactions, 2003, 5: 291). Therefore, the hemolytic anemia caused by puerarin is caused by puerarin itself.
Disclosure of Invention
The invention aims to provide a new medical application of methionine, namely the application of the methionine in a puerarin injection, and the methionine can effectively prevent and treat the untoward reaction of intravascular hemolysis induced by the puerarin.
Actually, the invention relates to the application of methionine in preparing puerarin injection compound preparation, and can also be temporarily matched with puerarin injection in the injection and transfusion modes, or the puerarin injection is applied after the methionine is applied in the injection and transfusion modes.
In order to achieve the purpose, the invention adopts the technical scheme that: new use of methionine in preparing puerarin injection is provided. The methionine and puerarin injection is temporarily matched and applied in the modes of injection and transfusion. The injection is prepared by applying methionine in injection and infusion modes and then applying puerarin injection.
The relevant content in the above technical solution is explained as follows:
1. in the scheme, the injection comprises the following medicines in parts by weight: l-50 parts of methionine, l-50000 parts of puerarin.
2. In the scheme, the injection also comprises 1-50 parts by weight of auxiliary materials and l-10000 parts by weight of water for injection. The auxiliary materials are sodium bicarbonate solution, glucose solution, propylene glycol solution, glucose saline, sodium chloride injection or normal saline.
3. In the scheme, the injection can be clinically acceptable injection, powder injection or infusion.
4. In the above scheme, the preparation method of the injection is as follows:
the powder for injection is prepared by mixing methionine and puerarin and sterilizing; or mixing methionine, puerarin and sodium chloride, dissolving in water for injection, adjusting pH to 5.0-8.5 with hydrochloric acid or sodium bicarbonate solution, filtering, sterilizing the filtrate, packaging in powder ampoule, and sterilizing;
the injection is prepared by the following steps. Mixing methionine, puerarin and sodium chloride, dissolving in water for injection, adjusting pH to 5.0-8.5 with hydrochloric acid or sodium bicarbonate solution, filtering, bottling the filtrate, and sterilizing. Or methionine is prepared from 5% glucose solution, 5% glucose saline, propylene glycol solution (prepared from propylene glycol and normal saline at volume ratio of 1:1, and containing propylene glycol 0.5 ml/ml), sodium chloride injection or normal saline by dissolving, mixing with puerarin injection, filtering, packaging the filtrate in ampoule, and sterilizing.
The infusion is prepared by mixing methionine, puerarin and sodium chloride, dissolving with injectable water, adjusting pH to 5.0-8.5 with hydrochloric acid or sodium bicarbonate solution, dissolving, filtering, bottling the filtrate in saline glass bottle, and sterilizing. Or methionine is prepared from 5% glucose solution, 5% glucose saline, propylene glycol solution (prepared from propylene glycol and normal saline at volume ratio of 1:1, and containing propylene glycol 0.5 ml/ml), sodium chloride injection or normal saline by dissolving, mixing with puerarin injection, filtering, packaging the filtrate in ampoule, and sterilizing.
In the scheme, the temporary matching application refers to that the puerarin injection is mixed with the methionine for transfusion or injection at the same time when being applied in a hospital.
In the above scheme, the application of the methionine and then the puerarin injection in the injection and transfusion manner means that the methionine and then the puerarin injection in the injection and transfusion manner are applied in a hospital.
Puerarin has effects of dilating coronary artery and cerebral vessels, reducing oxygen consumption of myocardium, and improving microcirculation platelet aggregation. Clinically, the traditional Chinese medicine composition is used for auxiliary treatment of coronary heart disease, angina, myocardial infarction, retinal artery and vein occlusion, sudden deafness, ischemic cerebrovascular disease, infantile viral myocarditis, diabetes and the like. Puerarin can be combined with methionine to make compound puerarin injection for preventing and treating various diseases, such as diabetic peripheral neuropathy, hypertension complicated with diabetes, diabetic nephropathy, acute cerebral infarction, stable angina pectoris, lower limb deep venous thrombosis and vertebrobasilar artery ischemia vertigo. However, puerarin in the puerarin-containing injection is very easy to cause intravascular hemolysis. The methionine not only has a plurality of physiological activities of protecting liver, strengthening brain and the like, but also has the function of antagonizing intravascular hemolysis adverse reaction induced by puerarin and improves the safety of puerarin injection administration.
The purpose and the achieved effect of the present invention will be further described below with reference to some tests.
The experiment refers to the technical guidance principle of research on the irritation and hemolysis of traditional Chinese medicines and natural medicines to carry out a preliminary test on the hemolysis test, and the result shows that 4-6mM puerarin can cause 10% hemolysis of rabbit red blood cells of 1%, the occurrence probability of the in vitro hemolysis test is 100%, the hemolysis test results are all reproduced, and the method can be repeated. The method can be used for finding potential accidental hemolysis of the injection, is a feasible test method for carrying out new drug development of the injection and judging whether accidental hemolysis exists, is beneficial to reducing adverse reactions and improving the safety of the injection.
The invention takes rabbits as an experimental animal model to research the action and the effect of methionine on the hemolytic adverse reaction of puerarin solution.
Action and effect of methionine on antagonizing hemolytic adverse reaction of puerarin-containing solution
Hemolysis test of puerarin injection
The influence of the combination of methionine and puerarin on rabbit erythrocytes was studied. The administration method of rabbit comprises dividing the group treated with puerarin and the group (puerarin injection + methionine) into 2 groups, each group containing 5 rabbits. The puerarin injection and methionine are administered by ear vein at a dose of 15 mg/kg per body mass per day-1Dosing. The puerarin-treated rabbits were administered with puerarin at 15 mg/kg per day according to body mass-1Dosing. 1 administration cycle, 10 d per cycle. Blood was collected before dosing and 24 h after dosing on day 6 of the week.
Adding methionine and puerarin into red blood cells of rabbit of puerarin injection, respectively, observing red blood cell state and hemolysis incidence after 10min, and using X2The test result of statistical analysis is tested to find the resistance of methionine to accidental hemolysis of puerarin injection. The results are now reported as follows:
1. experimental Material
1.1 test drugs
Methionine injection (I) is obtained from Beijing Solebao scientific and technological Co., Ltd., methionine 7.25mg is accurately weighed by an electronic balance, dissolved in physiological saline solution, and the methionine solution is quantitatively determined to 10mL by a 10mL volumetric flask, thus obtaining the injection (I) with the concentration of 4mmol-1. Filtering with microporous membrane (0.22 μm) for sterilization, and storing at 4 deg.C.
Injection agent 2: the injection (r) is diluted to 2 mmol.L with sterilized normal saline-110mL, stored at 4 ℃ until use.
Injection (c): the injection (r) is diluted to 1 mmol.L with sterilized normal saline-110mL, stored at 4 ℃ until use.
And 4, puerarin injection IV: 2mL of the puerarin powder is provided by Zhejiang Connbei pharmaceutical products GmbH, and the product batch number is 090501, and each mL of the injection contains 50mg of puerarin.
Puerarin injection (250 mM): accurately weighing 1.041g of puerarin powder (purchased from Jiangsu Tiancheng drug Co., Ltd.) by using an electronic balance, dissolving by using 40% dimethyl sulfoxide (DMSO, DZ0231 and AMRESCO), assisting in dissolving by using ultrasound, diluting the physiological saline solution to 9mL, fixing the volume of a volumetric flask to 10mL, and enabling the color of the solution to be colorless (in a configuration environment: carried out in an ultra-clean workbench). The solvent was 40% DMSO solution. Filtering with microporous membrane (0.22 μm) for sterilization, and storing at 4 deg.C.
Compound puerarin injection (sixty percent): 0.04mL of injection and 0.20 mL of injection are uniformly mixed to form 0.24mL of injection. Each mL of the injection contains 41.67mg of puerarin and 120.8 mug of methionine.
Compound puerarin injection (c): 0.04mL of injection and 0.20 mL of injection are uniformly mixed to form the injection (c), wherein the total volume is 0.24 mL. Each mL of the injection contains 41.67mg of puerarin and 60.4 mug of methionine.
Compound puerarin injection (b): 0.04mL of injection and 0.20 mL of injection are uniformly mixed and totally 0.24mL is prepared to form the injection. Each mL of the injection contains 41.67mg of puerarin and 30.2 mug of methionine.
Ninthly, the compound puerarin injection: 0.04mL of injection and 0.099 mL of injection are uniformly mixed to form 0.14mL of injection. Each mL of the injection contains 73.61mg of puerarin and 207.1 μ g of methionine.
Compound puerarin injection r: 0.04mL injection and 0.099 mL injection are mixed to total 0.14mL to form injection in the form of injection in the amount of R. Each mL of the injection contains 73.61mg of puerarin and 103.6 μ g of methionine.
Compound puerarin injection 11: mixing injection (0.04 mL) and injection (0.099 mL), and mixing to give injection (0.14 mL). Each mL of the injection contains 73.61mg of puerarin and 51.8 μ g of methionine.
1.2 Experimental animals
10 rabbits (about 2.5 Kg) are provided by the animal experiment center of northwest agriculture and forestry science and technology university. Feeding the chicken at the room temperature of 15-25 ℃ and the relative humidity of 50%.
1.3 reagents, instruments
Sodium chloride injection, Shiyao silver lake pharmaceutical Co Ltd; water for injection is prepared by self; TGL-16B high speed centrifuge, Hunan Star science instruments, Inc.; HPY-01B Biochemical incubator, Huangshi Hengfeng medical appliances Co., Ltd; BIO-RAD680 enzyme-linked immunosorbent assay device; the enzyme label is purchased from Jiangsu Haimen III and Xinya medical instrument factories and is purchased from Yanglinbao Xin equipment Co., Ltd. of Shaanxi province.
2 method
2.1 preparation of erythrocyte suspensions
10 rabbits are divided into puerarin injection group and puerarin injection + methionine treatment group, and blood is collected 24 h after 6 days of ear marginal vein injection. The hemolysis experiments were performed separately. 10mL of blood is collected from the heart of each rabbit, 160IU of heparin sodium (Jiangsu Wanbang Biochemical medicine, Inc.) is anticoagulated, then the rabbit is placed in a graduated centrifugal tube, the rabbit is centrifuged at 2000 r/min for 10min, the blood plasma is discarded, a proper amount of sodium chloride injection is added for washing, and the rabbit is centrifuged to discard the supernatant and the leucocyte layer. Adding appropriate amount of normal saline, shaking, centrifuging, and repeatedly washing for 3 times until the supernatant is colorless and transparent after centrifuging. The packed red blood cells were diluted with physiological saline to form an 11% (by volume) red blood cell suspension. This completes the preparation of the red blood cell suspension.
2.2 Puerarin solution in vitro hemolysis experiment design
Let the concentration of puerarin solution on erythrocytes be 6mM (0.00259 g.mL)-1). Setting a negative control group, a solvent control group (DMSO is used for replacing puerarin solution to act on erythrocytes), a drug treatment group and a positive control group. The puerarin solution was measured to have a pH of 7.16 using a METTLER TOLEDO benchtop pH meter.
The corresponding components were added to the tubes separately, taking care of the order of addition, as shown in Table 1 below. After each addition of one ingredient, shake gently. After all the components in the system are added into the system, the mixture is gently shaken and uniformly mixed, and then the mixture is placed in a biochemical incubator at 37 ℃ for incubation. After 10min hemolysis and coagulation reactions were observed. The condensation reaction determination method comprises: if the solution has reddish brown or brownish red flocculent precipitate, it will not disperse after shaking, indicating that there is agglutination of red blood cells, if the aggregate can be uniformly dispersed after shaking, it will be false agglutination, if the aggregate is not shaken, it will be true agglutination. The tubes were then centrifuged at 5000rpm/min and the color of the supernatant visually observed. The supernatant was collected and the light absorption (OD value) was measured at a wavelength of 540 nm. According to 2005 technical guidance principle of stimulation and hemolysis research of traditional Chinese medicine and natural medicine, the hemolysis rate (%) of each tube of each group is calculated according to a formula:
hemolysis rate (%) = (drug-treated OD value-negative control OD value)/(positive control OD value-negative control OD value)
Reference evaluation criteria: the hemolysis rate >5% indicates that hemolysis occurred and was statistically processed.
TABLE 1 puerarin solution and methionine in vitro hemolysis experiment grouping design
3 results
The puerarin is 15 mg/kg daily according to body mass-1When the dosage is treated, 15 mg.kg is simultaneously administered-1At the dose of methionine, no hemolysis was found in the experimental rabbits. The test also considers the influence of 40 mu M, 20 mu M and 10 mu M methionine on 5 rabbit red blood cells injected with puerarin when the concentration of the puerarin is 6mM, and simultaneously carries out the occasional hemolysis experimental study of the puerarin injection of the fourth and fifth, and the experimental results are all recorded in detail. By X2The results of the test statistical analysis are shown in Table 2.
Note: a P <0.01 compared to saline negative group; b P <0.01 compared with puerarin injection group
The results show that: the saline group showed no hemolysis, and the water for injection showed complete hemolysis: compared with the normal saline group, the puerarin Injection (IV) and (V) are all hemolyzed, and the occurrence rate of hemolysis is very different from that of the normal saline group (P is less than 0.01); the results of the hemolysis test are reproduced, which shows that the hemolysis test method is stable and reliable, and the test results can be repeated. Comparing with the fourth and the fifth groups of puerarin injections, the compound puerarin injections (P <0.01) have no hemolysis in the groups of (VI), (III; compared with the normal saline, the hemolysis incidence of each group of compound puerarin injections (P >0.05) and (b) does not differ from that of the normal saline; the compound puerarin injections (sixty percent, nine, eight, 11) have the same puerarin concentration (6 mM), but the compound puerarin injections (sixty percent, nine, seven, eight, nine) contain 40 muM, 20 muM and 10 muM methionine, and the puerarin (sixty percent, seven) do not contain methionine. The above results suggest: the methionine with different concentrations and the puerarin can resist hemolytic adverse reaction induced by the puerarin and reduce the incidence rate to the normal saline level.
The above experimental results show that: the puerarin can initiate hemolysis, the injection containing the puerarin can initiate hemolysis, and the hemolysis adverse reaction containing the puerarin can be eliminated after the methionine is added.
The above test results suggest: the puerarin injection and the injection prepared by the puerarin and the methionine have no hemolytic reaction.
Therefore, when the puerarin-containing injection is prepared or used, the methionine is added, so that hemolytic adverse reactions caused by the puerarin can be eliminated, and the safety of puerarin injection administration is improved.
The invention has the advantages that: when the puerarin-containing injection is prepared or applied, methionine is added, so that the injection has better antagonism to intravascular hemolysis adverse reaction induced by puerarin, and has the advantages of low price, no toxic or side effect and safety.
The invention is further described below with reference to the following examples:
the specific implementation mode is as follows:
example i: (preparation of Compound puerarin injection)
Taking 15mg of methionine and 10 g of puerarin, adding 9g of sodium chloride, adding water to 1000mL, adjusting the pH to 5.0-8.5 by using 1mol/l hydrochloric acid or sodium bicarbonate solution, filtering, encapsulating the filtrate in an ampoule of 2, 5 or 10mL, and sterilizing at 100 ℃ for 30min to obtain the injection. The product can be used for the adjuvant treatment of coronary heart disease, angina pectoris, myocardial infarction, retinal artery and vein occlusion, sudden deafness, ischemic cerebrovascular disease, infantile viral myocarditis, diabetes, etc. The product can be injected intravenously or intramuscularly, each time is l-500 mL, 1-3 times a day, l 0-20 days is a treatment course, and the product can be continuously used for 2-3 treatment courses.
Example 2: (preparation of Compound puerarin powder for injection)
Taking 30mg of methionine and 1g of puerarin, encapsulating in a 10mL ampoule of powder for injection, and sterilizing at 100 ℃ for 30min to obtain the powder for injection. The product can be used for the adjuvant treatment of coronary heart disease, angina pectoris, myocardial infarction, retinal artery and vein occlusion, sudden deafness, ischemic cerebrovascular disease, infantile viral myocarditis, diabetes, etc. When in application, the prepared powder injection of l to 5000mg is mixed with sodium chloride injection or normal saline injection evenly, and intravenous injection or intramuscular injection can be carried out, wherein l to 500mL of the powder injection is carried out each time, l to 3 times a day, 10 to 20 days are a treatment course, and the powder injection can be continuously used for 2 to 3 treatment courses.
Example 3: (preparation of Compound puerarin infusion)
Adding water into 7.5mg methionine, 2g puerarin and 9g sodium chloride to 1000mL, adjusting pH to 5.0-8.5 with lmol/l hydrochloric acid or sodium bicarbonate solution, filtering, bottling the filtrate in 250mL saline glass bottle, and sterilizing at 100 deg.C for 30min to obtain infusion. The product can be used for the adjuvant treatment of coronary heart disease, angina pectoris, myocardial infarction, retinal artery and vein occlusion, sudden deafness, ischemic cerebrovascular disease, infantile viral myocarditis, diabetes, etc. When the Chinese medicinal composition is applied, intravenous injection or intramuscular injection can be directly carried out, wherein the Chinese medicinal composition is used for 1-3 times per day by l-500 mL each time, and l 0-20 days are a treatment course and can be continuously used for 2-3 treatment courses.
The above embodiments are merely illustrative of the technical ideas and features of the present invention, and the purpose thereof is to enable those skilled in the art to understand the contents of the present invention and implement the present invention, and not to limit the protection scope of the present invention. All equivalent changes and modifications made according to the spirit of the present invention should be covered within the protection scope of the present invention.
Claims (7)
1. Application of methionine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection is provided.
2. Use according to claim 1, characterized in that: methionine is applied by infusion, and then puerarin injection is used.
3. Use according to claim 1, characterized in that: puerarin injection and methionine injection
Mixing before use, and applying in infusion mode.
4. Use according to claim 2, characterized in that: the methionine is firstly applied for transfusion and then applied
Is prepared from puerarin injection.
5. Use according to claim 1, characterized in that: comprises the following medicaments in part by weight: 1-50 parts of methionine and 1-50000 parts of puerarin.
6. Use according to claim 1, 2, 3, 4, characterized in that: contains 1-50 parts by weight of auxiliary materials.
7. An adjuvant according to claim 6, characterized in that: the auxiliary materials are sodium bicarbonate solution, glucose solution, propylene glycol solution or sodium chloride injection.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011556378.1A CN112438971A (en) | 2020-12-25 | 2020-12-25 | Application of methionine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011556378.1A CN112438971A (en) | 2020-12-25 | 2020-12-25 | Application of methionine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection |
Publications (1)
Publication Number | Publication Date |
---|---|
CN112438971A true CN112438971A (en) | 2021-03-05 |
Family
ID=74739240
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202011556378.1A Pending CN112438971A (en) | 2020-12-25 | 2020-12-25 | Application of methionine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN112438971A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113143861A (en) * | 2021-06-15 | 2021-07-23 | 华北制药股份有限公司 | Puerarin composition for injection and preparation method thereof |
-
2020
- 2020-12-25 CN CN202011556378.1A patent/CN112438971A/en active Pending
Non-Patent Citations (2)
Title |
---|
M C VISSERS 等: "Membrane changes associated with lysis of red blood cells by hypochlorous acid" * |
侯少贞: "葛根素注射液致溶血反应的机制研究" * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113143861A (en) * | 2021-06-15 | 2021-07-23 | 华北制药股份有限公司 | Puerarin composition for injection and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104825479B (en) | Icariside class compound, its preparation method and its people's cell is being promoted to generate gamma interferon effect and application in disease treatment | |
CN107012203A (en) | PDCD4 is used as depression and the/application of anti anxiety agent thing therapy target | |
Rappaport | Monolayer Cultures of Trypsinized Monkey Kidney Cells in Synthetic Medium. Application to Poliovirus Synthesis. | |
CN112438971A (en) | Application of methionine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection | |
TWI581793B (en) | Sodium methylarsonate is newly applied in the field of medical science as an inhibitor for glycoprotein in pathogens | |
CN112516125A (en) | Application of tyrosine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection | |
CN112315950A (en) | Application of phenylalanine in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection | |
CN112336710A (en) | Application of glutamine in preparing medicine for preventing and treating puerarin injection induced intravascular hemolysis | |
CN112451481B (en) | Application of gamma globulin in preparing medicine for preventing and treating intravascular hemolysis induced by puerarin injection | |
CN110590921A (en) | Human Kv1.3 type potassium ion channel activity inhibition peptide mimic, and preparation method and application thereof | |
CN112451653A (en) | Application of glutathione in preparation of medicine for preventing and treating intravascular hemolysis induced by puerarin injection | |
CN107922453A (en) | As the positive allosteric regulator of erythropoietin and Hematopoietin Receptors with treat erythropoietin lack disease noval chemical compound | |
CN102525910B (en) | Process for preparing penehyclidine hydrochloride injection | |
Mukusheva et al. | Synthesis and structure of new modified derivatives based on the quinine molecule and their biological activity | |
CN116077496B (en) | Application of shikonin combined with CM-272 in preparation of medicines for treating lung cancer | |
CN116211870A (en) | New application of androstane-4, 6,8 (9), 13 (14) -tetraene-3, 11, 16-trione | |
Alvarez et al. | Induction of sister chromatid exchanges in mouse fetuses resulting from maternal alcohol consumption during pregnancy | |
CN106606474A (en) | 3beta, 19alpha-hydroxy-urs-12-en-28-carboxylic acid injection, and preparation method and applications thereof | |
JPH0196124A (en) | Carcinostatic agent | |
CN110638747A (en) | Disodium adenosine triphosphate liposome nasal gel and application thereof | |
CN113908168A (en) | Application of pectolinarin in preparing anti-osteosarcoma medicine and anti-osteosarcoma medicinal preparation | |
CN104042602A (en) | Application of sodium glutamate in puerarin injection | |
WO2018133106A1 (en) | Ziyuglycogenin solid dispersion, preparation method therefor and use thereof | |
CN1051451C (en) | Anti-AIDS-virus drug composition | |
CN111643529A (en) | Application of crocodile blood in preparing anti-tumor and anti-virus medicines |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20210305 |